GERON CORP Debt Securities, Available-for-sale, Unrealized Loss Position
GERON CORP (GERN) had Debt Securities, Available-for-sale, Unrealized Loss Position of $216.35 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $216.35M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $170.93M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $49.25M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $50.31M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $216.35M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $170.93M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $49.25M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $50.31M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $140.28M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $90.37M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $171.72M 10-K · filed 2026-03-02 |
| 2024-09-30 | $14.83M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $312.29M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $185.85M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $166.52M 10-K · filed 2025-02-27 |
| 2023-09-30 | $351.58M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $285.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $209.29M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $104.16M 10-K · filed 2024-02-28 |
| 2022-09-30 | $161.03M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $170.74M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $155.04M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $133.58M 10-K · filed 2023-03-16 |
| 2021-09-30 | $72.44M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $77.70M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $69.10M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $56.85M 10-K · filed 2022-03-10 |
| 2020-09-30 | $53.59M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $127.28M 10-Q · filed 2020-08-06 |
| 2019-12-31 | $46.28M 10-K · filed 2021-03-11 |
| 2019-09-30 | $20.75M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $22.26M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $58.13M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $121.99M 10-K · filed 2020-03-12 |
| 2018-09-30 | $108.27M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $91.13M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |